Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299412 | 0.83 | SMN1; SMN2 (0.49) | JAK2GRM2PTGS2SMN1; SMN2 | |
| SCHEMBL20425267 | 0.81 | JAK2 (0.43) | JAK2L3MBTL1GRM2HRH3GRIA2 | |
| SCHEMBL23269469 | 0.80 | KMT2A (0.46) | JAK2L3MBTL1GRM2HRH3PTGS2 | |
| SCHEMBL8325711 | 0.80 | GRM2 (0.54) | JAK2L3MBTL1PIK3CAGRM2SMN1; SMN2 | |
| SCHEMBL79013 | 0.80 | GRM2 (0.43) | JAK2L3MBTL1PIK3CAMTORGRM2 | |
| SCHEMBL1553262 | 0.80 | L3MBTL1 (0.54) | JAK2L3MBTL1PTGS2 | |
| SCHEMBL19501381 | 0.79 | FKBP1A (0.47) | JAK2L3MBTL1GRM2MAPK1SMN1; SMN2 | |
| SCHEMBL5737672 | 0.79 | POLB (0.47) | JAK2GRM2MAPK1SMN1; SMN2 | |
| SCHEMBL3326531 | 0.79 | SMN1; SMN2 (0.59) | L3MBTL1GRM2MAPK1SMN1; SMN2 | |
| SCHEMBL15972059 | 0.78 | ALDH1A1 (0.42) | JAK2GRM2PTGS2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227417-A1 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | GEN1E LIFESCIENCES INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227417-A1 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPKAPK2 | JAK2 806/4885L3MBTL1 4021/4885PIK3CA 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.